Valuation: Cognition Therapeutics, Inc.

Market Cap 97.55M 85.33M 78.69M 72.74M 138M 9.3B 141M 942M 369M 4.58B 366M 358M 15.84B P/E 2026 *
-3.38x
P/E 2027 * -3.94x
Enterprise Value 97.55M 85.33M 78.69M 72.74M 138M 9.3B 141M 942M 369M 4.58B 366M 358M 15.84B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.63%
Yield 2026 *
-
Yield 2027 * -
1 day+1.87%
1 week-3.54%
Current month-5.22%
1 month-9.92%
3 months+23.84%
6 months-23.78%
Current year-19.26%
1 week 1
Extreme 1
1.18
1 month 0.93
Extreme 0.93
1.76
Current year 0.55
Extreme 0.5501
1.76
1 year 0.55
Extreme 0.5501
3.83
3 years 0.22
Extreme 0.2223
3.83
5 years 0.22
Extreme 0.2223
13.8
10 years 0.22
Extreme 0.2223
13.8
Manager TitleAgeSince
Chief Executive Officer 66 2020-03-26
Director of Finance/CFO 48 2023-04-30
Chief Tech/Sci/R&D Officer - 2023-12-31
Director TitleAgeSince
Director/Board Member 46 2015-06-30
Director/Board Member 69 2016-08-31
Director/Board Member 66 2019-02-28
Date Insider Type Main position Quantity % Market Cap.
06-16Free

Chairman

25,000 0.0279%
06-16Free

Director

25,000 0.0279%
06-16Free

Director

25,000 0.0279%
Change 5-day change 1-year change 3-year change Capi.($)
+1.87%-3.54%+85.22%-33.94% 95.76M
-0.38%+0.40%+71.69%+128.83% 56.71B
+4.91%-3.30%+71.97%+92.14% 51.3B
+1.48%+10.52%+23.01%+495.47% 25.26B
-0.59%-1.00%-16.73%-12.99% 23.65B
+3.93%+7.11%+44.20%-1.96% 18.69B
+2.01%+7.22%+41.55%-24.93% 17.71B
-6.84%+4.81%+201.88%+348.11% 17.7B
-0.92%+8.90%+38.48% - 14.26B
+1.76%+5.82%+31.23%+195.70% 14.1B
Average +0.72%+2.57%+59.25%+131.83% 23.95B
Weighted average by Cap. +1.06%+2.16%+58.78%+145.11%

Financials

2026 *2027 *
Net sales - -
Net income -32.22M -28.19M -25.99M -24.03M -45.66M -3.07B -46.43M -311M -122M -1.51B -121M -118M -5.23B -33.72M -29.5M -27.2M -25.15M -47.78M -3.22B -48.59M -326M -128M -1.58B -127M -124M -5.47B
Net Debt - -
Logo Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. It is developing other product candidates in the area of synucleinopathies.
Employees
14
Date Price Change Volume
26-07-09 US$1.090 +1.87% 1,981,491
26-07-08 US$1.070 -0.93% 2,570,783
26-07-07 US$1.080 +0.93% 1,950,302
26-07-06 US$1.070 -8.55% 2,649,489
26-07-02 US$1.170 +3.54% 2,059,084
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.090USD
Average target price
3.500USD
Spread / Average Target
+221.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CGTX Stock